DekaBank Deutsche Girozentrale Buys 111,898 Shares of Bristol Myers Squibb Company (NYSE:BMY)

DekaBank Deutsche Girozentrale increased its stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 3.0% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,894,388 shares of the biopharmaceutical company's stock after purchasing an additional 111,898 shares during the period. DekaBank Deutsche Girozentrale owned approximately 0.19% of Bristol Myers Squibb worth $232,263,000 as of its most recent filing with the SEC.

Several other large investors have also bought and sold shares of BMY. Brighton Jones LLC boosted its stake in shares of Bristol Myers Squibb by 33.4% during the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company's stock valued at $1,116,000 after purchasing an additional 4,935 shares in the last quarter. Bank Pictet & Cie Europe AG bought a new stake in shares of Bristol Myers Squibb in the 4th quarter valued at $13,094,000. Proficio Capital Partners LLC bought a new stake in shares of Bristol Myers Squibb in the 4th quarter valued at $240,000. Larson Financial Group LLC increased its stake in shares of Bristol Myers Squibb by 10.6% in the 4th quarter. Larson Financial Group LLC now owns 17,100 shares of the biopharmaceutical company's stock valued at $967,000 after acquiring an additional 1,639 shares in the last quarter. Finally, OFI Invest Asset Management bought a new stake in Bristol Myers Squibb during the 4th quarter valued at $45,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, EVP Samit Hirawat acquired 4,250 shares of the stock in a transaction on Friday, April 25th. The stock was acquired at an average price of $47.58 per share, with a total value of $202,215.00. Following the completion of the transaction, the executive vice president owned 83,513 shares of the company's stock, valued at $3,973,548.54. This represents a 5.36% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.09% of the company's stock.

Bristol Myers Squibb Trading Up 1.0%

Shares of Bristol Myers Squibb stock traded up $0.48 on Tuesday, hitting $46.97. The stock had a trading volume of 619,267 shares, compared to its average volume of 12,826,156. The company has a quick ratio of 1.17, a current ratio of 1.28 and a debt-to-equity ratio of 2.65. Bristol Myers Squibb Company has a one year low of $39.50 and a one year high of $63.33. The stock has a market cap of $95.58 billion, a price-to-earnings ratio of 17.58, a PEG ratio of 1.39 and a beta of 0.36. The stock's 50-day simple moving average is $47.69 and its two-hundred day simple moving average is $53.50.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping analysts' consensus estimates of $1.50 by $0.30. Bristol Myers Squibb had a return on equity of 87.62% and a net margin of 11.38%. The company had revenue of $11.20 billion during the quarter, compared to analyst estimates of $10.77 billion. During the same quarter last year, the firm posted ($4.40) earnings per share. The firm's revenue was down 5.6% on a year-over-year basis. As a group, sell-side analysts predict that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 1st. Shareholders of record on Thursday, July 3rd will be given a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a yield of 5.28%. The ex-dividend date of this dividend is Thursday, July 3rd. Bristol Myers Squibb's dividend payout ratio is currently 92.88%.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. The Goldman Sachs Group restated a "neutral" rating and set a $55.00 price target (down previously from $67.00) on shares of Bristol Myers Squibb in a research note on Tuesday, April 8th. Cantor Fitzgerald reissued a "neutral" rating and issued a $55.00 price target on shares of Bristol Myers Squibb in a report on Tuesday, April 22nd. William Blair reaffirmed a "market perform" rating on shares of Bristol Myers Squibb in a report on Friday, April 25th. UBS Group decreased their price target on Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a research report on Friday, April 11th. Finally, Argus upgraded Bristol Myers Squibb to a "hold" rating in a research report on Friday, April 25th. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $58.00.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.